1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

09 Sep 2024
Admin
News Article

Exyte Acquires TTP Group to Boost Biopharma and Life Sciences Growth

Overview

Exyte has announced plans to acquire TTP Group, a well-known consulting and engineering firm for the pharmaceutical and chemical industries in Europe.

Exyte’s leadership believes that combining TTP’s engineering expertise with their project execution capabilities will solidify their position in Europe’s biotech and pharma markets.

TTP Services

TTP offers a broad range of services, from feasibility studies to construction management and validation services.
Exyte, TTP’s minority shareholders, and financial investor Robus Capital have signed a definitive agreement, with the purchase price remaining confidential.
The acquisition is subject to regulatory approval.

About TTP

TTP is a trusted partner for major biotech, pharma, and chemical companies in Europe, operating through its brands, Pharmaplan and Triplan.
The company provides end-to-end services, including engineering, procurement, construction management, and validation.
Exyte plans to integrate TTP’s operations into its own Biopharma and Life Sciences activities in Europe, creating a stronger partnership to serve the growing biotechnology and pharmaceutical industry across the continent.

TTP Projects

TTP undertakes a wide range of projects, from revamping existing plants to constructing new ones, and has a strategic presence across Europe with 27 locations in Austria, Belgium, France, Germany, and Switzerland.
In 2023, TTP’s workforce of around 1,000 employees generated sales of approximately €170 million.
The company aims to maintain its profitable growth trajectory in the years ahead.

About The Acquisition

The acquisition to enhance their ability to offer comprehensive services, from strategic planning to the construction of high-tech facilities.
TTP’s skilled workforce, including engineers, architects, and project managers, will contribute to Exyte’s future growth and success.

Companies Commitment

Both companies share a commitment to providing innovative and sustainable solutions for their clients, and they see the merger as a positive step toward continued growth in the booming pharmaceutical facilities market.

Increasing Investments

With increasing investments in pharmaceutical production facilities driven by population growth, aging demographics, and new technologies such as mRNA, the demand for new manufacturing capacities is set to rise.
Exyte and TTP will be well-positioned to meet these demands with flexible, digital, and sustainable solutions.

Exyte’s Biopharma and Life Sciences division is its second-largest segment by revenue, generating €580 million in 2023. Order intake rose by 12% to €650 million, and the company aims to grow this segment’s revenue beyond €1.5 billion in the medium term.

Exyte’s Latest Project

Recently, Exyte completed a groundbreaking project to build one of the fastest-ever greenfield drug substance facilities, taking less than 22 months from design to validation at an mRNA competence centre in Germany.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!